Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Head & Neck 1Breast 1

Conditions

Stomach Neoplasms 2Esophageal Squamous Cell Carcinoma 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Esophageal Neoplasms 1

Interventions

Cisplatin 117Oxaliplatin 111Fluorouracil 100Capecitabine 90Docetaxel 69Leucovorin 60Irinotecan 57Paclitaxel 49S 1 (combination) 38pembrolizumab 33Trastuzumab 31Radiotherapy 25Bevacizumab 20Nivolumab 19Epirubicin 19titanium silicide 18Surgical Procedures, Operative 17Carboplatin 17Ramucirumab 15Cetuximab 15Gastrectomy 13apatinib 12Everolimus 12Gemcitabine 11Albumin-Bound Paclitaxel 10Neoadjuvant Therapy 8Folfox protocol 8Drug Therapy 8Chemotherapy, Adjuvant 8Radiation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Stomach Neoplasms × elgemtumab × Clear all
NCT01598077 2020-12-19

A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer

Novartis

Phase 1 Completed
54 enrolled
BreastGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Stomach Neoplasms

NCT01602406 2020-12-19

Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer

Novartis

Phase 1 Completed
64 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡